Serum CYFRA21-1 as a novel biomarker for predicting progressive pulmonary fibrosis in non-IPF interstitial lung disease, a cohort study [0.03%]
血清CYFRA21-1作为非特发性肺纤维化间质性肺病患者进展性肺纤维化的新型生物标志物的队列研究
Guoxin Zhang,Ming Sun,Hao Cao et al.
Guoxin Zhang et al.
Background: Progressive pulmonary fibrosis (PPF) represents a challenging phenotype of interstitial lung disease (ILD), characterised by functional deterioration and radiological progression despite treatment. The identif...
Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study [0.03%]
重度哮喘患者从奥马珠单抗换用抗IL-5/IL-5受体生物制剂的临床转归：一项回顾性队列研究
Fatma Arzu Akkuş,Fatih Çölkesen,Tuğba Önalan et al.
Fatma Arzu Akkuş et al.
Background: Severe asthma (SA) is a heterogeneous disease composed of various clinical phenotypes, and criteria for selecting the most appropriate biological agent remain unclear. Therefore, when optimal control cannot be...
Ten-year survival, trends and risk stratification of newly diagnosed idiopathic pulmonary arterial hypertension in China: insights from a national multicenter prospective registry [0.03%]
中国新诊断特发性肺动脉高压10年生存率、趋势和危险分层的启示：一项全国多中心前瞻性注册登记研究
Yifan Wu,Yuling Qian,Ruilin Quan et al.
Yifan Wu et al.
Background: Data on the 10-year survival of incident IPAH in China is lacking. The changing trend of characteristics and survival of IPAH over the past decade has yet been demonstrated. The 4-stratum risk model needs furt...
Global, regional and national burden of asthma attributable to metabolic diseases from 1990 to 2021 and projected trends to 2040 [0.03%]
1990年至2021年全球、区域和国家哮喘归因于代谢性疾病的疾病负担及至2040年的预测趋势
Zhi-Qiang Zhang,Jing-Yang Li,Chi-Yi Fu et al.
Zhi-Qiang Zhang et al.
Asthma is a prevalent inflammatory condition of the lower respiratory tract, affecting over 272 million people worldwide. Although prevalence and mortality rates have declined, asthma continues to burden healthcare systems, particularly in ...
Efficacy and safety of anlotinib combined with immune checkpoint inhibitors in the treatment of extensive-stage small cell lung cancer: a meta-analysis based on real-world data [0.03%]
安罗替尼联合免疫检查点抑制剂治疗广泛期小细胞肺癌的疗效和安全性：真实世界数据Meta分析
Yuying Yan,Xuebin Yang,Xu Yan et al.
Yuying Yan et al.
Objective: This research intended to ascertain the clinical efficacy and safety of anlotinib plus immune checkpoint inhibitors (ICIs) in patients suffering from extensive-stage small cell lung cancer (ES-SCLC). ...
Bidirectional causal association and shared anti-inflammatory target of asthma and atopic dermatitis: a Mendelian randomization and colocalisation study [0.03%]
哮喘和特应性皮炎之间的双向因果关系及共同的抗炎靶点：孟德尔随机化及共定位研究
Jirui Bi,Jihong Bi,Xing Ni et al.
Jirui Bi et al.
Prognostic role of pretreatment serum α-hydroxybutyrate dehydrogenase in patients with small cell lung cancer [0.03%]
前期血清α-羟丁酸脱氢酶对小细胞肺癌患者的预后价值
Qizhong Xu,Maoquan Liang,Fan Zhang et al.
Qizhong Xu et al.
Background and objectives: The role of pretreatment serum α-hydroxybutyrate dehydrogenase (α-HBDH) in small cell lung cancer (SCLC) prognosis prediction remains unknown. We sought to investigate the influence of pretrea...
New insights on Bronchial Artery Embolization (BAE) for hemoptysis: a systematic review [0.03%]
支气管动脉栓塞术治疗咯血的新见解：系统性回顾
Paolo Ravetta,Marie Bruyneel,Michael Vouche
Paolo Ravetta
Background: Bronchial Artery Embolization (BAE) is a well-established, non-surgical treatment for hemoptysis. This systematic review aims to update the current literature on BAE for hemoptysis, focusing on indications, te...
Optimization of intranasal bleomycin dose for effective pulmonary fibrosis induction in mice with minimal animal distress [0.03%]
优化鼻内给药bleomycin剂量以有效诱导小鼠肺纤维化且最小化动物痛苦的方法
Anita Salmaso,Anna Valeria Samarelli,Giulia Yuri Moscatiello et al.
Anita Salmaso et al.
Background: Pulmonary fibrosis is a progressive interstitial lung disease driven by aberrant alveolar epithelial repair and dysregulated crosstalk with mesenchymal cells, leading to myofibroblast activation and excessive ...
Potential drug targets for chronic obstructive pulmonary disease in the plasma proteome identified through Mendelian randomization [0.03%]
通过孟德尔随机化在血浆蛋白组中鉴定慢性阻塞性肺疾病的潜在药物靶点
Qinyao Jia,Jiangfeng Xiao,Wenbo Zhang et al.
Qinyao Jia et al.
Background: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. Current options such as glucocorticoids and bronchodilators improve symptoms but carry risks, including infection and...